GlassScriptPhysician profile
Katie Burlen-Davis
NPI 1306485636
$1,862.85
in general payments reported to CMS, 2019-2025
13 companies · $557 in 2025
The $557 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $714 · 2022: $403 · 2023: $188 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $424.69 | 2021 | |
| Beigene USA, INC. | $239.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $210.68 | 2023-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $188.22 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $149.92 | 2022 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2025 | |
| Stryker Corporation | $116.12 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Genzyme Corporation | $88.68 | 2025 | |
| Sk Life Science, INC. | $75.42 | 2025 | Xcopri |
| Alkermes, INC. | $68.44 | 2023 | Lybalvi |
| Abbvie INC. | $65.33 | 2022 | |
| Aimmune Therapeutics, INC. | $60.59 | 2025 | Zenpep |
| Nevro Corp. | $49.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Burlen-Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.